Patent 11021437

Litigation summary

Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.

Active provider: Google · gemini-2.5-pro

PTAB activity (1)

AIA trial proceedings — IPR, PGR, CBM — filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced directly from the PTAB Trial API.

  • IPR2025-00874IPRfiled May 16, 2025vs. Aquestive Therapeutics, Inc.Discretionary Denial

Cached for 24 hours. Status strings are sourced verbatim from the PTAB API; the colored badge is our heuristic classification.

Cases on file (1)

Group view →

Specific litigation cases in our database that name US patent 11021437. The free-form analysis below may also discuss cases beyond this list.

Litigation summary

Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.

✓ Generated

As of April 26, 2026, US patent 11,021,437 is involved in at least one known litigation, an Inter Partes Review (IPR) proceeding before the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO).

Details of the case are as follows:

Case: Inter Partes Review
Petitioner: Aquestive Therapeutics, Inc.
Patent Owner/Defendant: Iono Pharma, LLC
Jurisdiction: Patent Trial and Appeal Board (PTAB)
Case Number: IPR2025-00874
Filing Date: May 16, 2025
Status: The petition for inter partes review was denied.

In this proceeding, Aquestive Therapeutics, Inc. challenged the validity of claims 1-3 of the '437 patent. The challenge was based on the argument that the claimed inventions were obvious in light of prior art. However, the PTAB exercised its discretion and denied the institution of the IPR.

Generated 5/14/2026, 6:48:44 AM